Last update 27 Feb 2026

Ad26.HPV18

Overview

Basic Info

Drug Type
Recombinant vector vaccine, Prophylactic vaccine
Synonyms
HPV18 Ad26-vectored vaccine, JNJ 63682931, JNJ-63682931
Target-
Action
stimulants
Mechanism
Immunostimulants
Therapeutic Areas
Infectious Diseases
Active Indication-
Inactive Indication
Human Papillomavirus Infection
Originator Organization
Janssen Vaccines & Prevention BV
Active Organization-
Inactive Organization
Janssen Vaccines & Prevention BVBavarian Nordic A/SBavarian Nordic A/S
License Organization-
Drug Highest PhaseDiscontinuedPhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Ad26.HPV18
NCT03610581
/ TerminatedPhase 1/2
A Randomized, Double-blind, Placebo-controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise Healthy Women With HPV16 or 18 Infection of the Cervix
100 Clinical Results associated with Ad26.HPV18
Login to view more data
100 Translational Medicine associated with Ad26.HPV18
Login to view more data
100 Patents (Medical) associated with Ad26.HPV18
Login to view more data
100 Deals associated with Ad26.HPV18
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Human Papillomavirus InfectionPhase 2
United States
Bavarian Nordic A/SBavarian Nordic A/S
27 Sep 2018
Human Papillomavirus InfectionPhase 2
United States
Janssen Vaccines & Prevention BV
27 Sep 2018
Human Papillomavirus InfectionPhase 2
Belgium
Janssen Vaccines & Prevention BV
27 Sep 2018
Human Papillomavirus InfectionPhase 2
Belgium
Bavarian Nordic A/SBavarian Nordic A/S
27 Sep 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT03610581 (CTgov)
Phase 1/2
Human Papillomavirus Infection
9
adenovirus serotype 26. human papillomavirus (Ad26.HPV)16+Ad26.HPV18+modified vaccinia Ankara (MVA).HPV16/18
(Regimen 1)
eawijbdzyi = msuknlccur wnsqkfhfej (gvplfzmimh, wctgjllrtb - hlkjjoxsgg)
View more
-
09 Nov 2021
placebo
(Placebo)
eawijbdzyi = rfrvjjxcze wnsqkfhfej (gvplfzmimh, igzmzosxfn - xnofhdfiap)
View more
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free